← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biostream Therapeutics, Inc.
Cambridge, MA
$1,364,690
Total funding
10
Grants
Funding mix
By agency
NIH$1,364,690 · 10
By mechanism
R41$876,469 · 5
R43$488,221 · 5
Investigators at Biostream Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Novel pharmacotherapies for treatment of ADHD$295,466
R41 · FY2003 · HD
Neuroprotective Drugs for Spinal Cord Injury$208,726
R41 · FY2001 · NS
BEHAVIORAL STUDIES ON NOVEL MONOAMINE UPTAKE INHIBITORS$137,375
R41 · FY2000 · DA
Neuroadaptive effects after chronic CTDP 31446 treatment$103,437
R41 · FY2001 · DA
POLYMERIC MICELLAR CONTRAST AGENTS FOR CT ANGIOGRAPHY$98,742
R43 · FY2000 · HL
TC-99M ADENINE NUCLEOTIDE POLYPHOSPHATE IMAGING AGENTS$98,125
R43 · FY2000 · CA
TECHNETIUM-99M LABELED FATTY ACID ANALOGS FOR IMAGING$98,075
R43 · FY2000 · HL
Novel Tc99m-Chelates for Imaging Monoamine Transporters$96,766
R43 · FY2002 · NS
POLYPHARMACOPHORE MODEL FOR TREATMENT OF COCAINE ABUSE$96,513
R43 · FY2000 · DA
BEHAVIORAL EVALUATION OF NOVEL DAT ANTAGONIST$86,025
R41 · FY2000 · DA
BEHAVIORAL STUDIES ON NOVEL MONOAMINE UPTAKE INHIBITORS$24,121
R41 · FY2001 · DA
BEHAVIORAL EVALUATION OF NOVEL DAT ANTAGONIST$21,319
R41 · FY2000 · DA